We are pleased to announce the official inauguration of the first biosafety level 3 laboratory module (#BSL3) in #Italy!
This is not only a significant achievement but also a starting point for the future of the #biotech sector.
The module, which is already operational, allows for the study of pathogens such as SARS-CoV-2, Dengue, Zika, and tuberculosis, and represents a fundamental step towards creating innovative “Made in Italy” therapies.
“The module will be a driver of knowledge and #innovation for the sector” said our CEO, Luigi Aurisicchio. “This facility enables us to push the boundaries of #research, paving the way for new #vaccines and treatments that will strengthen both local and global #health resilience” added our CTO Giuseppe Roscilli.
The BSL3 module enables the identification of molecular targets suitable for designing vaccines and other drugs capable of fighting dangerous hashtag#diseases for humans, testing their effectiveness both in vitro and in vivo.
Our company’s broader goal is to build a network of regional, national, and international partners to collaborate with, in order to develop new drugs quickly and improve the epidemic preparedness of our country and the whole world.
For this reason, we are especially pleased to have had with us the representatives from various important organizations and institutions, including Dr. Giuseppe Biazzo, the new President of Unindustria Roma – Frosinone – Latina – Rieti – Viterbo, Prof. Rino Rappuoli, who gave an enlightening speech on the future of diseases and their economic and social impact, Giancarlo De Matthaeis, President of Labozeta SpA, a key partner in the realization of the module together with Teco SRL, Lorenzo Tagliavanti, President of the Camera di Commercio Roma, On. Edy Palazzi, Councilor of the Regione Lazio, On. Luciano Ciocchetti, Deputy of the Camera dei deputati, and Sen. Marco Silvestroni, Senator of the Senato della Repubblica.
We conclude with the words of our COO, Emanuele Marra: “It has been a challenging journey where our resilience was put to the test. Building this module was a true feat. But we are convinced that ‘Made in Italy’ is much more than just the origin of certain ingredients. It is the ability of our people to develop the therapies of the future. At Takis, we don’t aim to be a big company at all costs; we aim to do great #research, and this module will let us do exactly that!
